Biocon plans to list its subsidiary Syngene with stock exchanges in July

23 Apr 2015 Evaluate

Biocon is all set to get its subsidiary Syngene listed with the stock exchanges in July. In this regard, the company has filed the draft red herring prospectus on April 22 with the market regulator, Securities and Exchange Board of India (SEBI).

Biocon, which owns an 86% stake in the R&D subsidiary, is planning to raise Rs 1,000 crore through the public issue.

Further, the company will be offloading at least 10 per cent of Syngene equity as it needs funds to support some of its research and development programmes.

Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

366.40 -6.25 (-1.68%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×